Current and Future Trends in Myeloproliferative Neoplasms

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

An overview of the treatment options for patients with polycythemia vera.

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.

Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.

Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.

Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.

The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.

Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.

Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.

A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.

Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.

The panelists conclude their discussion by highlighting investigational agents to look forward to.